PO.MCB06.02 · 分子与细胞生物学

整合转录组学与表观基因组学分析,研究吸烟诱导的cg05575921低甲基化增加肺癌风险的机制

Integrated transcriptomic and epigenomic analysis to study the mechanism by which smoke-induced hypomethylation of cg05575921 increases lung cancer risk

海报缩略图:整合转录组学与表观基因组学分析,研究吸烟诱导的cg05575921低甲基化增加肺癌风险的机制
编号 1950 展板 2 时间 4/20 09:00–12:00 区域 Section 22 主讲 Matthew Gladstone, BS
分会场 DNA Methylation
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Matthew Gladstone1, Khoi Huynh2, Chunli Yan1, Kimberly D. Siegmund3, Aram Modrek2, Ite Offringa1

1Surgery, Cancer Biology, USC Norris Comprehensive Cancer Center, Los Angeles, CA,2USC Norris Comprehensive Cancer Center, Los Angeles, CA,3USC, Los Angeles, CA

摘要 Abstract

中文摘要
肺癌是美国癌症死亡的首要原因。最常见的亚型是肺腺癌(LUAD),起源于肺泡上皮。烟草烟雾和污染在LUAD风险中起关键作用,并在众多全表观基因组关联研究中与DNA甲基化改变相关。cg05575921的低甲基化是最显著的变化之一,可预测吸烟者中所见肺癌增加风险的30%以上。然而,这种甲基化丢失与肺癌风险相关联的机制仍不清楚。我们此前表明,位于芳香烃受体抑制因子基因(AHRR)内含子3中的cg05575921邻接一个烟草烟雾可诱导的增强子。烟雾暴露后,AHRR是两兆碱基窗口内唯一表达上调的基因。AHRR是芳香烃受体(AHR)诱导的解毒反应的负反馈调节因子。与AHR类似,AHRR与伴侣蛋白ARNT结合。然而,与开启解毒基因的AHR/ARNT异二聚体不同,AHRR/ARNT异二聚体下调解毒反应。我们假设,长期烟草烟雾暴露触发AHRR的适应不良性表达,cg05575921的低甲基化是邻近增强子激活的副产物,而AHRR的组成性表达阻止了保护性异生物质解毒反应,从而增加肺癌风险。我们利用独特的永生化人肺泡上皮细胞,通过以下方式确定增强子和cg05575921在AHRR表达中的作用:i)使用Oxford Nanopore长读长测序研究该区域在烟草烟雾暴露过程中随时间变化的DNA甲基化改变;ii)使用CRISPR/Cas9杂合缺失已知增强子和/或CpG,以确定其对增强子/CpG缺失等位基因和对照等位基因AHRR表达的影响;iii)使用可诱导的AHRR基因,检验AHRR组成性表达对香烟烟雾诱导的异生物质反应基因的影响。理解cg05575921低甲基化为何与肺癌风险强烈相关,可能有助于设计缓解烟雾暴露影响的策略。 本研究由烟草相关疾病研究计划的T31IP1913、USC/Norris综合癌症中心的癌症表观基因组调控试点奖、Norris综合癌症中心核心基金NIH/NCI P30CA014089以及Keck医学院院长奖学金资助。MAG和IAO是CaRE 2(癌症研究教育与参与健康中心)的成员,该中心由NIH/NCI基金U54CA233396、U54CA233444和U54233465资助。
查看英文原文 English abstract
Lung cancer is the leading cause of cancer death in the US. The most common subtype is lung adenocarcinoma (LUAD), arising out of the alveolar epithelium. Tobacco smoke and pollution play a key role in LUAD risk and have been associated with changes in DNA methylation in numerous epigenome-wide association studies. Hypomethylation of cg05575921 is one of the most significant changes, predicting over 30% of the increased risk of lung cancer seen in smokers. However, the mechanism by which this methylation loss is linked to lung cancer risk remains unknown. We previously showed that cg05575921, located in intron 3 of the gene aryl hydrocarbon receptor repressor ( AHRR ), borders a tobacco smoke-inducible enhancer. Upon smoke exposure AHRR is the only gene within a two megabase window whose expression increases. AHRR is a negative feedback regulator of aryl hydrocarbon receptor (AHR) induced detoxification responses. Like AHR, AHRR binds to the partner protein ARNT. However, unlike the AHR/ARNT heterodimer, which turns on detoxification genes, the AHRR/ARNT heterodimer downregulates the detoxification response. We hypothesize that prolonged tobacco smoke exposure triggers maladaptive expression of AHRR , that hypomethylation of cg05575921 is a byproduct of the adjacent enhancer activation, and that constitutive expression of AHRR prevents protective xenobiotic detoxification responses, thereby increasing lung cancer risk. Using our unique immortalized human alveolar epithelial cells, we are determining what role the enhancer and cg05575921 play in AHRR expression by i) using Oxford Nanopore long-read sequencing to study DNA methylation changes in the region over time during tobacco smoke exposure, ii) using CRISPR/Cas 9 to heterozygously delete the known enhancer and/or the CpG to determine the effects on the expression of AHRR from the enhancer/CpG-deleted and control alleles, iii) using an inducible AHRR gene to test the effects of constitutive expression of AHRR on the xenobiotic response genes induced by cigarette smoke. Understanding why cg05575921 hypomethylation is strongly associated with lung cancer risk may help devise strategies to mitigate the effects of smoke exposure. Supported T31IP1913 from the Tobacco-Related Disease Research Program, an Epigenomic Regulation in Cancer Pilot ward from the USC/Norris Comprehensive Cancer Center, the Norris Comprehensive Cancer Center core grant NIH/NCI P30CA014089, and a Keck School of Medicine Dean's Fellowship. MAG and IAO are members of CaRE 2 , the Cancer Research Education and Engagement Health Center, supported by NIH/NCI grants U54CA233396, U54CA233444, and U54233465.
利益披露 Disclosure
M. Gladstone, None.. K. Huynh, None.. C. Yan, None.. A. Modrek, None.. I. Offringa, None.

← 返回 AACR 2026 检索